Isolation of new flavonoid and lignan derivatives shows selective cytotoxicity in OVCAR3 cells, suggesting potential therapeutic applications.
An investigation of a cytotoxic MeOH extract of the branches of Beilschmiedia yunnanensis, collected in Vietnam, led to the isolation of four new compounds (1–4). Two of these, isolated from a CHCl3-soluble partition, were characterized as the furofuran-type neolignans, beilschmiedianins A (1)[(7R,7′R,8S,8′S,8″R)-4′,4″,9′′-trihydroxy-3,5,3′,3′′-tetramethoxy-4,8′′-oxy-7,9′:7′9-diepoxy-8,8′-sesquilignan-7′′-one)] and B (2) [(7R,7′R,7″R,8S,8′S,8″R)-9″-feruloyl-4′,4′′-dihydroxy-3,5,3′,3′′-tetramethoxy-4,8″-oxy-7,9′:7′,9-diepoxy-8,8′-dilignan-7″-ol]. In turn, the flavonoid glycosides 3 and 4 were obtained from an EtOAc-soluble partition and were assigned as (2R,3R)-dihydrokaempferol-5-O-β-l-arabinosyl-(2→1)-α-l-rhamnopyranoside and (2R,3R)-dihydrokaempferol-5-O-β-l-arabinopyranoside, respectively. The structures of these new compounds were determined using a combination of spectroscopic and spectrometric methods. Additionally, the known dilignan, (−)-9,9′-O-diferuloylsecoisolariciresinol (5), showed selective cytotoxicity against the OVCAR3 ovarian cancer cell line, with an IC50 value of 0.51 μM. Mechanistic studies showed that compound 5 increased the cPARP levels and decreased the expression of BCL-2 in OVCAR3 cells.
No takes yet. Share an insight, caveat, or question.
Terrasson et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: